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Abstract
Aims/hypothesis—Improved biomarkers are acutely needed for the detection of developing 
type 1 diabetes, prior to critical loss of beta cell mass. We previously demonstrated that elevated 
beta cell microRNA 21 (miR-21-5p) in rodent and human models of type 1 diabetes increased beta 
cell apoptosis. We hypothesised that the inflammatory milieu of developing diabetes may also 
increase miR-21-5p in beta cell extracellular vesicle (EV) cargo and that circulating EV 
miR-21-5p would be increased during type 1 diabetes development.
Methods—MIN6 and EndoC-βH1 beta cell lines and human islets were treated with IL-1β, IFN-
γ and TNF-α to mimic the inflammatory milieu of early type 1 diabetes. Serum was collected 
weekly from 8-week-old female NOD mice until diabetes onset. Sera from a cross-section of 19 
children at the time of type 1 diabetes diagnosis and 16 healthy children were also analysed. EVs 
were isolated from cell culture media or serum using sequential ultracentrifugation or ExoQuick 
precipitation and EV miRNAs were assayed.
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Results—Cytokine treatment in beta cell lines and human islets resulted in a 1.5- to threefold 
increase in miR-21-5p. However, corresponding EVs were further enriched for this miRNA, with a 
three- to sixfold EV miR-21-5p increase in response to cytokine treatment. This difference was 
only partially reduced by pre-treatment of beta cells with Z-VAD-FMK to inhibit cytokine-induced 
caspase activity. Nanoparticle tracking analysis showed cytokines to have no effect on the number 
of EVs, implicating specific changes within EV cargo as being responsible for the increase in beta 
cell EV miR-21-5p. Sequential ultracentrifugation to separate EVs by size suggested that this 
effect was mostly due to cytokine-induced increases in exosome miR-21-5p. Longitudinal serum 
collections from NOD mice showed that EVs displayed progressive increases in miR-21-5p 
beginning 3 weeks prior to diabetes onset. To validate the relevance to human diabetes, we assayed 
serum from children with new-onset type 1 diabetes compared with healthy children. While total 
serum miR-21-5p and total serum EVs were reduced in diabetic participants, serum EV 
miR-21-5p was increased threefold compared with non-diabetic individuals. By contrast, both 
serum and EV miR-375-5p were increased in parallel among diabetic participants.
Conclusions/interpretation—We propose that circulating EV miR-21-5p may be a promising 
marker of developing type 1 diabetes. Additionally, our findings highlight that, for certain 
miRNAs, total circulating miRNA levels are distinct from circulating EV miRNA content.
Keywords
Beta cell signal transduction; Cell lines; Human; Prediction and prevention of type 1 diabetes
Introduction
The global incidence of type 1 diabetes has been consistently rising by 3–5% a year, 
affecting millions of people worldwide [1, 2]. Type 1 diabetes develops over time, with 
progressive dysfunction and destruction of pancreatic beta cells, such that by the time of 
clinical disease presentation, affected individuals have lost a substantial portion of their 
functional beta cell mass [3, 4]. Emerging data have suggested that the beta cell itself may 
contribute to type 1 diabetes development via activation of intrinsic stress pathways that 
exacerbate or accelerate autoimmune mediated destruction [5, 6]. These data highlight a 
need for robust biomarkers of beta cell health to identify and monitor beta cell dysfunction. 
Such strategies would not only improve our understanding of the contribution made by beta 
cell dysfunction to the natural history of type 1 diabetes but would also enable the detection 
of developing diabetes, permitting earlier administration of disease-modifying therapies.
Extracellular vesicles (EVs) are membrane-bound nanoparticles released from all cell types 
that function in intercellular communication [7, 8]. EVs are often broadly classified into 
three categories, exosomes, microvesicles and apoptotic bodies, based on their size, cellular 
origin and formation mechanism [9]. Research continues to elucidate distinct biological 
functions among these groups [10, 11]. The molecular cargo of EVs partially mirrors the 
cellular contents of their cells of origin but can also reflect regulated changes occurring in 
conditions of stress or disease [12, 13]. Because of this, EVs have generated interest as non-
invasive biomarkers of multiple pathologic processes [14, 15].
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We and others have previously demonstrated that beta cell microRNA 21 (miR-21-5p) is 
increased in response to treatment with inflammatory cytokines and in models of type 1 
diabetes, and that miR-21-5p has a negative impact on beta cell survival and function [7, 16–
18]. In this context, increased miR-21-5p appears to be specific to beta cell inflammation, as 
treatment with high glucose to mimic hyperglycaemia or tunicamycin to induce endoplasmic 
reticulum stress does not affect miR-21-5p expression [7]. Several groups have reported that 
circulating levels of miR-21-5p are increased in longstanding type 1 diabetes [19, 20]. 
However, the aetiology of these observed increases in circulating miR-21-5p, and 
miR-21-5p’s potential as a biomarker of developing type 1 diabetes, remain unexplored. 
Based on our earlier work, we predicted that beta cell EV miR-21-5p would be increased by 
exposure to the microenvironment of developing type 1 diabetes and, as a result, that 
circulating EV miR-21-5p could function as a biomarker of developing type 1 diabetes. 
Here, we detail our findings using both in vitro and in vivo models, as well as comparing 
clinical samples taken from children at the time of type 1 diabetes diagnosis with samples 
taken from healthy non-diabetic children.
Methods
Culture of cells and human islets
MIN6 cells, originally obtained from J. Miyazaki (Osaka University Graduate School of 
Medicine, Suita, Osaka, Japan), were cultured as described previously, but with the use of 
EV-depleted FBS (ThermoFisher, Waltham, MA, USA) [21]. EndoC-βH1 (EndoC) cells, 
originally obtained from R. Scharfmann (Research Center Growth and Signaling, Université 
Paris Descartes, Paris, France), were cultured in serum-free media, as previously described 
[22]. Human islets were obtained through the Integrated Islet Distribution Program, which is 
exempt from institutional review board approval, and cultured in Standard Islet Medium 
(Prodo Labs, Aliso Viejo, CA, USA) supplemented with Human AB Serum (Prodo), 
glutamine and glutathione (Prodo) and 10 μg/ml ciprofloxacin (Corning, Corning, NY, 
USA), and depleted of EVs by overnight ultracentrifugation. The authenticity of cell lines 
was verified through maintenance of glucose-stimulated insulin secretion. Cells were 
routinely tested for mycoplasma with QuickTest Mycoplasma Detection Kit (Biotool, 
Houston, TX, USA). Absence of EVs in the media prior to culture was verified by 
nanoparticle tracking analysis (NTA). To model the inflammatory milieu of type 1 diabetes, 
samples were exposed to cytokine mix consisting of 5 ng/ml IL-1β, 100 ng/ml IFN-γ and 10 
ng/ml TNF-α (R&D Systems, Minneapolis, MN, USA) for 24 h, as described previously 
[7]. Available cells and islet preparations were not randomised but divided evenly for 
comparison of control and cytokine treatments among islets from the same donor or cells 
from the same parent cells. To inhibit cytokine-induced apoptosis, 25 μmol/l of the pan-
caspase inhibitor Z-VAD-FMK (R&D Systems) was added to the cells concurrently with 
cytokines. Data are representative of at least three independent experiments.
Isolation of EVs
Total EVs were isolated from culture media using ExoQuick TC reagent (System 
Biosciences, Palo Alto, CA, USA) and circulating EVs were isolated from 50 μl of serum 
using ExoQuick reagent (System Biosciences) following manufacturer’s guidelines. 
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Sequential ultracentrifugation was used to separate EVs by size. The samples were 
centrifuged at 800 g for 15 min to remove dead cells and cellular debris, after which the 
supernatant fraction was centrifuged at 2000 g to pellet large EVs/apoptotic bodies. To 
collect microvesicles, the supernatant fraction from the previous step was centrifuged at 
10,000 g and the resulting supernatant fraction was centrifuged at 100,000 g to pellet the 
exosomes. The remaining EV-depleted supernatant was also retained for analysis. EVs 
collected at each step were washed in PBS following described protocols and collected by 
centrifugation at appropriate speed [23, 24]. Isolation and relative purity of the EVs were 
confirmed by NTA, transmission electron microscopy (TEM) and immunoblot.
PCR
RNA isolation and reverse transcription were performed using miRNeasy and miScript II RT 
kits (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. Where 
applicable, RNA integrity was determined with Agilent Small RNA kit using Bioanalyzer 
instrument (Agilent Technologies, Santa Clara, CA, USA). Quantitative real-time PCR 
(qPCR) was performed using the SooFast EvaGreen Supermix (BioRad, Hercules, CA, 
USA) and a Mastercycler ep realplex instrument (Eppendorf, Happauge, NY, USA). Due to 
low concentrations, droplet digital PCR (ddPCR) was performed as previously described to 
quantify serum EV miR-21-3p [25]. Primer for RNU6-1 was purchased from Sigma (St. 
Louis, MO, USA) and primers for miR-21-3p, miR-375-5p and the C. elegans miR-39 
spike-in control were purchased from Qiagen. The following primer sequence was used to 
amplify miR-21-5p: CTAGCTTATCAGACTGATGTTG. Qiagen’s universal primer was 
used as the reverse primer in all reactions. Relative miRNA levels from EV isolates were 
established against C. elegans miR-39 mimic spike-in control, and from cells and tissues 
relative to RNU6-1, using the ΔΔCq method.
Immunoblot analysis
Immunoblot analysis was performed as described previously [7]. Antibodies (diluted 
1:1000) against calreticulin, CD9 (10292-1-AP and 20597-1-AP; ProteinTech, Rosemon, IL, 
USA) and CD63 (ABIN1440014; Antibodies-Online, Atlanta, GA, USA) were used for 
primary detection. Fluorescently labelled secondary antibodies (Jackson ImmunoResearch, 
West Grove, PA, USA) were used at 1:20,000 dilution. Signal detection was conducted on a 
LI-COR Odyssey imager (LI-COR Biosciences, Lincoln, NE, USA). The antibodies were 
selected based on published literature. For further validation, protein lysates were serially 
diluted and subjected to immunoblot analysis. Distinct band signal of appropriate molecular 
weight and of intensity proportional to sample dilutions were considered validated for target 
detection by immunoblot.
NTA
Samples enriched for EVs of interest were analysed for concentration and size distribution 
with dynamic light scattering using the ZetaView instrument (ParticleMetrix, Meerbusch, 
Germany). All data acquisition was conducted at room temperature. NTA measurements 
were recorded and analysed at 11 positions per sample with ZetaView Analyse software 
(ParticleMetrix).
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TEM imaging
EV-enriched sample preparations were fixed in EM-grade fixative containing 2% (wt/vol.) 
glutaraldehyde and 2% (wt/vol.) paraformaldehyde in 0.1 mol/l buffered phosphate for at 
least 30 mins at 4°C. After fixation, samples were placed on 200 mesh silicon monoxide 
formvar-coated grids and stained with NanoVan (Nanoprobes, Yaphank, NY, USA). Images 
were taken on an FEI Technai G2 Spirit TEM microscope (FEI, Houston, TX, USA).
Animal studies
Eight-week-old female NOD (NOD/ShiLtJ) mice and non-obese diabetes-resistant (NOR/
LtJ; NOR) control mice (The Jackson Laboratory, Bar Harbor, MI, USA) were followed 
with weekly blood glucose measurements and serum collections until the onset of diabetes 
(defined as first of two consecutive blood glucose values > 4.4 mmol/l) [26]. All mice were 
euglycaemic and tested naive at initial evaluation. Non-diabetic NOD mice were followed 
until 20 weeks of age to rule out development of diabetes. Terminal serum was collected and 
islets were isolated as previously described [27]. For islet isolation and terminal serum 
collection, a sample size of five NOR and four NOD mice were used. Sample sizes of n = 5 
for NOR control mice and n = 7–9 (depending on time to diabetes) for NOD mice were 
chosen for longitudinal experiments because of anticipated variability in prediabetic mice. 
Blood collection for serum isolation and glucose measurements were done via tail vein nick. 
Blood glucose was measured using an AlphaTRAK glucometer (Abbott Laboratories, 
Abbott Park, IL, USA) following manufacturer’s instructions. Serum samples were isolated 
using a Microvette CB 300 system for capillary blood collection (Sarstedt, Numbrecht, 
Germany). Pancreatic islets were isolated using collagenase digestion [27]. The mice were 
maintained within the Indiana University Laboratory Animal Resource Center under 
pathogen-free conditions, in accordance with the Guide for the Care and Use of Laboratory 
Animals. All mice were kept in a standard light–dark cycle with ad libitum access to chow 
and water. All protocols were approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee.
Human studies
This study was approved by the Indiana University Institutional Review Board. Informed 
consent was obtained from parents with assent from children as required. Random serum 
samples were obtained from 19 children diagnosed with type 1 diabetes by a paediatric 
endocrinologist within 3 days of clinical diagnosis. HbA1c levels were measured at diagnosis 
using either the BayerA1cNow system or the Bayer DCA 2000 (Bayer, Tarrytown, NY, 
USA). Samples were collected in serum separator tubes and serum was isolated by 
centrifugation and stored at −80°C. Exclusion criteria included diabetic ketoacidosis 
requiring an intensive care unit stay, diabetes other than type 1 diabetes, history of prior 
chronic illness known to affect glucose metabolism or use of medications known to affect 
glucose metabolism. Serum from 16 healthy non-diabetic children (as a control group) was 
obtained from a biorepository at Indiana University School of Medicine. All available 
samples from the type 1 diabetes and healthy control groups were assayed in this analysis. 
All samples were analysed simultaneously by blinded laboratory personnel.
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Statistical analyses
GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) was used for statistical 
analyses. Significance was assessed by a two-tailed Student’s t test or Mann–Whitney U test 
(for nonparametric distributions), one-way ANOVA with Holm–Sidak’s multiple 
comparisons test or two-way ANOVA with Sidak’s multiple comparisons test for analysis of 
more than two groups. Spearman’s correlation analyses were used to measure monotonic 
relationships. p values were considered statistically significant when p < 0.05.
Results
Beta cell EV miR-21-5p release is increased after exposure to inflammatory cytokines
We and others have reported increased beta cell miR-21-5p expression after treatment with 
an inflammatory cytokine mix to model the type 1 diabetes inflammatory milieu [7, 17]. 
Consistent with this, we observed a 1.5- to threefold increase in miR-21-5p expression in 
MIN6 mouse insulinoma beta cells, EndoC human beta cells and human islets after 
treatment for 24 h with IL-1β, INF-γ and TNF-α (Fig. 1a–c). To determine whether this 
model of proinflammatory cytokine stress increases beta cell EV miR-21-5p, we also 
quantified miR-21-5p in EVs from MIN6 cells, EndoC cells and human islets after treatment 
for 24 h with cytokine mix. Here, cytokine exposure induced a three- to sixfold increase in 
total EV miR-21-5p (Fig. 1d–f), suggesting a selective enrichment of EV miR-21-5p in 
response to cytokines, rather than a non-specific reflection of cytokine-induced increase in 
intracellular miR-21-5p.
To understand whether this difference in EV miR-21-5p correlated with increased release of 
EVs under inflammatory conditions, we performed NTA to determine EV quantity and size 
distribution. No significant differences in either the size distribution or particle concentration 
were detected in MIN6 or EndoC cells, or in human islets after 24 h of cytokine treatment 
(Fig. 1g–i). These data suggest that the cytokine-induced increase in beta cell EV miR-21-5p 
is specifically due to increases in vesicle cargo.
We further wanted to discover whether the cytokine-induced increase in EV miR-21-5p was 
related to cytokine-induced beta cell apoptosis. We measured EV miR-21-5p in MIN6 and 
EndoC cells treated with both cytokines and the pan-caspase inhibitor Z-VAD-FMK (Fig. 
1k,l). Here, cytokine-induced increases in EV miR-21-5p were partially abrogated by 
addition of Z-VAD-FMK. However, EV miR-21-5p levels remained approximately twofold 
increased compared with EVs from vehicle-treated cells, suggesting that the cytokine-
induced increase in beta cell EV miR-21-5p is only partially related to beta cell death.
Cytokine-induced increase in beta cell EV miR-21-5p is predominantly due to beta cell 
exosome miR-21-5p
Next, we asked whether the cytokine-induced increase in beta cell EV miR-21-5p was 
specific to a particular EV subtype. We used sequential ultracentrifugation to separate EVs 
by size, allowing for enrichment for larger vesicles (apoptotic bodies), intermediate-sized 
vesicles (microvesicles) and smaller vesicles (exosomes) [10, 28]. Immunoblot analysis and 
TEM were performed to validate isolations (Fig. 2a,b). Media remaining post-centrifugation 
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was also collected to assess the presence and relative levels of EV-independent miR-21-5p 
release. miRNA quality and quantity were validated by spectral analysis, which revealed that 
miRNA concentrations in EV preparations from the vehicle- and cytokine-treated samples 
were similar (electronic supplementary material [ESM] Fig. 1). qPCR of each fraction 
revealed that in MIN6 cells, miR-21-5p was only increased by cytokines in the exosome 
fraction (Fig. 2c). In EndoC cells and human islets, cytokine-induced increase in miR-21-5p 
occurred in the apoptotic body and exosome fractions (Fig. 2d,e). NTA of ultracentrifugation 
fractions revealed much higher total concentrations of exosomes than either microvesicles or 
apoptotic bodies (Fig. 2f–h). In aggregate, these data suggest that exosomes are the 
predominant type of vesicle contributing to the cytokine-induced increase in beta cell EV 
miR-21-5p.
Progressive elevation in circulating EV miR-21-5p precedes the onset of diabetes in NOD 
mice
Based on the increased release of beta cell EV miR-21-5p in response to cytokine exposure 
ex vivo, we predicted that circulating EV miR-21-5p would also be increased during 
development of type 1 diabetes in vivo. To test this, we used the NOD mouse model of type 
1 diabetes. Consistent with our data in cytokine-treated cells and human islets, islets from 
female diabetic NOD mice at the time of diabetes onset exhibited a 2.5-fold increase in 
miR-21-5p expression compared with islets from NOR control mice (Fig. 3a). Next, we 
isolated EVs from terminal serum of diabetic mice and detected an approximate tenfold 
increase in serum EV miR-21-5p compared with NOR control mice (Fig. 3b). EV isolation 
was validated by western blotting for EV markers CD9 and CD63, which were enriched in 
the EV samples as compared with the original serum samples; as expected, the endoplasmic 
reticulum marker calreticulin was grossly depleted in the EV isolates (Fig. 3c).
To assess changes in circulating EV miR-21-5p during type 1 diabetes development, we 
collected weekly serial serum samples from NOD mice starting at 8 weeks of age until the 
time of diabetes onset (Fig. 3d, n = 7–9 per timepoint depending on time of diabetes onset). 
We observed an age-dependent increase in miR-21-5p in the circulating EVs of prediabetic 
NOD mice starting at 12 weeks of age (Fig. 3e). To establish temporal relationships to 
diabetes development we normalised these values to age-matched NOR control mice and 
plotted the data according to relative time to diabetes onset. This revealed a progressive 
increase in EV miR-21-5p starting 3 weeks before development of hyperglycaemia. (Fig. 
3f). NTA of these circulating EVs revealed no significant changes in the EV concentration 
relative to either age or diabetes onset (Fig. 3g,h). These data confirmed that progressive 
increases in serum EV miR-21-5p predate hyperglycaemia during developing diabetes in this 
mouse model of type 1 diabetes.
miR-21-5p is increased in circulating EVs from children with new-onset type 1 diabetes
To establish relevance to human disease, we analysed clinical serum samples from 19 
paediatric volunteers with new-onset type 1 diabetes and 16 healthy paediatric control 
participants. Demographic characteristics are presented in Table 1. No significant differences 
in age, sex or BMI percentile for age were present between the groups. We quantified total 
serum miR-21-5p, total serum EVs and circulating EV miR-21-5p. In contrast to reports in 
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longstanding type 1 diabetes, total serum miR-21-5p was decreased in participants with 
recent-onset type 1 diabetes compared with the healthy control group (Fig. 4a) [19, 20]. 
However, consistent with our in vitro and NOD mouse findings, levels of serum EV 
miR-21-5p were increased threefold in samples from children with type 1 diabetes (Fig. 4b). 
Furthermore, when normalised to the total serum miR-21-5p level, the miR-21-5p levels 
from circulating EVs of participants with type 1 diabetes were fivefold higher than in control 
participants, confirming that the increase in serum miR-21-5p was specific to EVs (Fig. 4c).
NTA, performed on serum samples to assess differences in the overall concentration and size 
distribution of circulating EVs, revealed a reduced number of circulating EVs (particularly 
smaller EVs) in type 1 diabetes samples (Fig. 4d–f). Normalisation of serum EV miR-21-5p 
to total particle count also revealed increased serum EV miR-21-5p in children with type 1 
diabetes (Fig. 4g), consistent with our in vitro findings wherein increased EV miR-21-5p 
was related to increased EV miR-21-5p cargo rather than being reflective of increased EV 
release. We measured correlations between serum EV miR-21-5p and age, BMI percentile 
and HbA1c for diabetic and healthy participants. In the healthy individuals, younger age 
correlated with higher EV miR-21-5p levels (rs = −0.506, p = 0.0474; ESM Fig. 2a). 
However, this relationship was not present in participants with type 1 diabetes (ESM Fig. 
2b). We did not detect any correlations between BMI percentile or HbA1c and EV 
miR-21-5p levels. Similarly, no differences were detected based on sex.
Given that miR-21-3p originates from the same precursor miRNA as miR-21-5p, we 
predicted that circulating EV miR-21-3p may be increased in samples from participants with 
type 1 diabetes [29]. Consistent with prior reports in individuals at risk of type 1 diabetes 
[30], total serum miR-21-3p was increased in samples from participants with type 1 diabetes 
(ESM Fig. 2c). In contrast, median serum EV miR-21-3p levels were lower in samples from 
the type 1 diabetes group, despite there being considerable overlap in individual values 
between the two groups (ESM Fig. 2d).
We also asked whether our observed differences in serum and EV miRNAs would apply to a 
different miRNA biomarker of diabetes. We chose to measure miR-375-5p, which has been 
proposed as a circulating biomarker of beta cell death (Fig. 4h,i) [31, 32]. In contrast to 
miR-21-5p and miR-21-3p, in participants with type 1 diabetes, miR-375-5p was similarly 
increased in both serum and in serum EVs. We next examined associations between the 
relative levels of serum EV miR-21-5p and miR-375-5p among participants with diabetes. 
Although there was overlap in some individuals, the levels of the two microRNAs were not 
correlated overall, with some individuals displaying predominant elevations in either serum 
EV miR-21-5p or serum EV miR-375-5p (Fig. 4j).
Discussion
Our findings demonstrate that beta cell EV miR-21-5p cargo is increased in response to 
treatment with inflammatory cytokines. This increase was predominantly due to cytokine-
induced effects on beta cell exosome miR-21-5p and was only partially blocked by 
inhibition of apoptosis. We also report the novel observation that circulating EV miR-21-5p 
may be a biomarker of developing type 1 diabetes, in that progressive elevations in serum 
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EV miR-21-5p preceded hyperglycaemia in NOD mice and were present in children with 
new-onset type 1 diabetes.
Prior miRNA profiling in beta cells has demonstrated that the exosome contents differ from 
the cytoplasmic contents of cells of origin [33]. Specifically, several reports have 
demonstrated that beta cell EVs and their cargo have physiological relevance to the type 1 
diabetes microenvironment [6, 17, 33–39]. Islet EVs contain beta cell autoantigens and are 
able to increase antigen presentation and inflammatory cytokine production by antigen-
presenting cells, as well as stimulate endothelial cell angiogenesis [6, 34, 35, 39]. Incubation 
of human islets with circulating EVs from individuals with type 1 diabetes reduces glucose-
stimulated insulin secretion [40]. Prior work has also shown that exosomes from cytokine-
treated parent beta cells have a miRNA-dependent pro-apoptotic effect on recipient beta 
cells [33]. Our data point to an enrichment in the cytokine effect on miR-21-5p within beta 
cell exosomes, relative to intracellular miR-21-5p. Based on our previous report that 
miR-21-5p increases beta cell apoptosis, it is tempting to speculate that exosome miR-21-5p 
may be involved in the pro-apoptotic effect of exosomal miRNA transfer from cytokine-
treated cells [7].
We observed clear differences between circulating total miR-21-5p and EV miR-21-5p 
levels. Although long-term incubation of islets with cytokines has been reported to increase 
exosome release, we did not observe any change in beta cell or islet EV quantity after 24 h 
of cytokine treatment [6]. Lack of an increase in total EV count in islets or serum from 
individuals with type 1 diabetes suggests that our observed increases in EV miR-21-5p are 
related to increases in miR-21-5p cargo per EV. Our findings of parallel levels of 
miR-375-5p in total serum and serum EVs suggest that differential miRNA concentrations in 
serum vs serum EVs is not universal. These differences could reflect the pathophysiological 
process associated with release of the miRNA being studied [41]. For example, miR-375-5p 
may be non-selectively released by dying beta cells, as both EV-independent circulating 
miRNA and in EVs, while miRNAs reflecting other aspects of the diabetic islet 
microenvironment, such as miR-21-5p, could be more selectively packaged into EVs [41]. In 
aggregate, these findings confirm the importance of defining circulating EV miRNA content 
in addition to total circulating miRNA. Future work is needed to better understand the 
physiology of selective changes in beta cell EV miRNA cargo.
Our findings of decreased serum miR-21-5p in children with type 1 diabetes are in contrast 
to several published reports of increased circulating miR-21-5p in individuals with more 
established type 1 diabetes [19, 20]. However, reports describing total circulating miRNAs 
in new-onset type 1 diabetes or in those at risk of diabetes, which would be more clinically 
consistent with our study population, have not described elevated circulating miR-21-5p 
levels [30, 42, 43]. Although we did observe a clear subset of individuals with type 1 
diabetes that displayed elevations in EV miR-21-5p, with half of our diabetes samples above 
the range for healthy volunteers, there was variation among individuals with type 1 diabetes 
as a group. Similarly, significant variation existed in serum EV miR-375-5p values among 
study participants with type 1 diabetes. This variation likely reflects the heterogeneous 
nature of type 1 diabetes, which has been observed in other clinical cohorts, and may also 
explain differences in reports of levels of circulating miRNAs from small cross-sectional 
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studies [20, 25, 43–45]. Our finding that serum EV miR-21-5p and EV miR-375-5p levels 
were not necessarily correlated highlights the benefit of including multiple miRNAs as 
complementary tools to identify a signature of developing type 1 diabetes.
miR-21-5p is widely abundant, and released into circulation from multiple tissue sources. 
This contributes another likely source of variation to our study and significantly limits work 
to define the biomarker potential of circulating miRNAs in general [46]. However, our 
observations of consistent increases in EV miR-21-5p after cytokine exposure and before 
diabetes onset in the NOD mouse suggest that beta cell EV miR-21-5p is feasibly a major 
contributor to our observed signal in serum. Emerging strategies to isolate islet or beta cell-
derived EVs from the circulation are likely to increase the specificity of this assay and allow 
for earlier and more precise detection of developing type 1 diabetes [38]. Alternatively, 
removal of EVs derived from other tissues or identification of exosome subpopulations 
responsible for increased exosome miR-21-5p may provide a more robust signal [10, 11, 
28].
In aggregate, our findings point to circulating EV miR-21-5p as a promising biomarker of 
developing type 1 diabetes. Future studies will define the pathophysiological significance of 
EV miR-21-5p transfer to recipient beta cells in the progression to type 1 diabetes and 
establish whether beta cell EV miR-21-5p transfer represents a feasible therapeutic target. 
Studies are also needed to identify EV surface proteins that allow for enrichment of beta 
cell-specific EVs, and to define other beta cell EV miRNAs affected during the development 
of type 1 diabetes. Prospective evaluations of individuals are indicated to determine whether 
glycaemic control affects circulating EV miR-21-5p and whether levels are predictive of 
differences in type 1 diabetes clinical outcomes, such as honeymoon duration or loss of 
endogenous C-peptide secretion.
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Refer to Web version on PubMed Central for supplementary material.
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Research in context
What is already known about the subject?
• EV contents change over the course of disease development.
• miR-21-5p is increased in beta cells and mouse and human islets under 
proinflammatory conditions.
• Elevated levels of miR-21-5p are detrimental to beta cell survival.
What is the key question?
• Does the inflammatory milieu of type 1 diabetes increase miR-21-5p levels in 
pancreatic beta cell EVs, and could this increase be detected in circulation?
What are the new findings?
• Beta cell EV miR-21-5p cargo is increased in models of inflammatory stress.
• Elevations in serum EV miR-21-5p precede the onset of diabetes in NOD 
mice.
• Although total serum miR-21-5p is decreased, serum EV miR-21-5p is 
increased in individuals with new-onset type 1 diabetes. By contrast, miR-375 
is increased in both total serum and in serum EVs in individuals with new-
onset type 1 diabetes
How might this impact on clinical practice in the foreseeable future?
• Robust biomarkers of beta cell health could ultimately allow improved 
detection of preclinical type 1 diabetes and earlier administration of 
prevention strategies
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Fig. 1. 
Inflammatory cytokines increase beta cell EV miR-21-5p cargo. MIN6 and EndoC beta cells 
and human islets were treated with vehicle or a mix of IL-1β, INF-γ and TNF-α for 24 h. 
(a–c) miR-21-5p expression was assessed in MIN6 cells (n=3) (a), EndoC cells(n=6) (b) and 
human islets (n-10)(c);. (d–f) miR-21-5p levels were assessed in EVs from MIN6 cells (n=3) 
(d), EndoC cells (n=3) (e) and human islets (n=6) (f);. (g–i) NTA was performed to profile 
EV particle concentration and size distribution in MIN6 cells (n=3) (g), EndoC beta cells 
(n=3)(h) and human islets (n=3) (i). (j, k) MIN6 cells (n=3) (j) and EndoC cells (n=3) (k) 
were treated with inflammatory cytokines or cytokines in combination with the pan-caspase 
inhibitor Z-VAD-FMK. Effects on relative levels of EV miR-21-5p were assessed by qPCR. 
Results are displayed as mean ± SD; *p≤0.05, **p≤0.01 and ***p≤0.001. White circles, 
vehicle; black circles, cytokines. Cyto, cytokines; Veh, vehicle; RQ, relative quantity
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Fig. 2. 
Cytokine-induced increase in beta cell EV miR-21-5p is predominantly due to changes in 
exosome cargo. Media from vehicle- and cytokine-treated MIN6 cells, EndoC cells and 
human islets was separated by sequential centrifugation into large EV (apoptotic bodies), 
intermediate-sized EV (microvesicles) and small EV (exosomes) fractions. EV-depleted 
media was also retained. (a, b) Immunoblot (a) and TEM (b) analysis of EndoC cell-derived 
EVs was used to validate EV isolation by serial ultracentrifugation. TEM images display 
representative data from three independent experiments. Scale bars, 400 nm. (c–e) Relative 
levels of miR-21-5p were assessed by qPCR. (n=3 in MIN6 and EndoC cells; n=5 in human 
islets) (f–h) NTA of each ultracentrifugation fraction from EndoC cells was used to establish 
EV quantity and size distribution; (n=3 in MIN6 and EndoC cells; n=5 in human islets). 
White bars, vehicle-treated media; black bars, cytokine-treated media. Results are displayed 
as mean ± SD; **p≤0.01 and ***p≤0.001. EXO, exosomes; MV, microvesicles; RQ, relative 
quantity
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Fig. 3. 
Elevation in circulating EV miR-21-5p precedes onset of diabetes in NOD mice. (a, b) 
qPCR was performed to quantify relative levels of EV miR-21-5p in islets (a) and terminal 
serum (b) of diabetic NOD mice (n=4) compared with NOR controls (n=5). (c) Specificity 
of EV isolation was validated by western blotting of total serum and circulating EVs, probed 
for EV markers CD63 and CD9 and the endoplasmic reticulum marker calreticulin. (d) 
Longitudinal weekly serum collection and blood glucose assessment of NOD (n=7–9) and 
control NOR (n=5) mice were performed, starting at 8 weeks (wks) of age until either 
development of diabetes or 20 weeks of age. (e) qPCR was performed to quantify serum EV 
miR-21-5p in NOD mice vs NOR control mice according to age (n=3–9/group). (f) Serum 
EV miR-21-5p in NOD mice and age-matched NOR control mice was analysed in relation 
to diabetes onset (defined as first glucose >4.4 mmol/l). (n=3–9/group) (g, h) NTA of serum 
EVs in NOD mice showed no significant changes with relation to age (g) or diabetes onset 
(n=3–9/group) (h). Results are displayed as mean ± SD; †p=0.053, *p≤0.05, **p≤0.01 and 
***p≤0.001. White circles, NOR; black circles, NOD. BG, blood glucose; RQ, relative 
quantity, T1D, type 1 diabetes
Lakhter et al. Page 17
Diabetologia. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. 
Circulating EV miR-21-5p is elevated in children with new-onset type 1 diabetes. (a, b) 
Serum samples from healthy control children and children with new-onset type 1 diabetes 
were assessed for relative levels of circulating miR-21-5p in whole serum (a) and in 
circulating EVs (b). (c) Circulating EV miR-21-5p normalised to total serum miR-21-5p. 
(d–f) NTA was performed to quantify serum EV concentration and size distribution. (e) 
Quantification of total particle concentration by group. (f) Quantification of particle size by 
group. (g) Serum EV miR-21-5p level normalised to total serum particle number. (h, i) 
Relative levels of total serum miR-375-5p (h) and circulating EV miR-375-5p (i) were also 
quantified. (j) Relationship between serum EV miR-21-5p and EV miR-375-5p in samples 
from children with type 1 diabetes. (k) EV isolation from serum was validated by TEM; a 
representative image from three independent experiments is shown. Scale bar, 400 nm. 
Results are shown as median ± interquartile range (a–c, e–j) or mean ± SEM (d); *p≤0.05, 
**p≤0.01 and ***p≤0.001. White circles, healthy controls, n=16; black circles, type 1 
diabetes, n=19. HC, healthy controls; RQ, relative quantity; T1D, type 1 diabetes
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Table 1
Demographic characteristics of study participants
Variable Healthy controls (n=16) Type 1 diabetes (n=19) p value
Age, years 10.5 (9–12) 10.5 (8–12) 0.8579
Male sex, % 62.5 62.5 1.00
BMI percentile 84 (72.5–89.5) 52.5 (32.5–87.5) 0.1343
HbA1c, mmol/mol NA 100 (89–111) NA
HbA1c, % NA 11.3 (10.3–12.3) NA
Results are displayed as median (interquartile range)
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